Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

This publication has 13 references indexed in Scilit:

• Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
• Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance
  Current Medical Research and Opinion, 2006
• Treatment for Adult HIV Infection
  JAMA, 2006
• Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
  The Lancet, 2006
• Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome
  Antiviral Therapy, 2006
• Effects of drug resistance on viral load in patients failing antiretroviral therapy
  Journal of Medical Virology, 2006
• Emerging anti-HIV drugs
  Emerging Drugs, 2005
• Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
  New England Journal of Medicine, 2003
• Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
  New England Journal of Medicine, 2003
• New antiretroviral drugs
  Clinical Microbiology & Infection, 2003